E-viri
Recenzirano
-
Hayette, Sandrine; Michallet, Mauricette; Baille, Marie-Laurence; Magaud, Jean-Pierre; Nicolini, Franck E.
Leukemia research, 09/2005, Letnik: 29, Številka: 9Journal Article
Quantitative monitoring of imatinib mesylate (IM)-resistant, mutated BCR-ABL + cells during the follow-up of CML could be useful for optimizing therapeutic management. We retrospectively analyzed T315I mutated BCR-ABL clones throughout the CML history of two patients by nested-PCR-RFLP. At the time of progression, the T315I mutation represented 100% of the BCR-ABL transcripts. During follow-up, we showed that (i) despite a molecular response to IM, a high proportion of T315I transcripts were present (>85%) and predictive of relapse, (ii) interruption of IM and switching to other therapies resulted in a significant reduction in mutant transcript level while total BCR-ABL + transcripts remained stable.
